Sign In
Buy AZN
$181.02
+4.59 (+2.60%)
At Close: Jun 23, 2026
AZN Wins FDA Nod for Expanded Use of Rare Disease Drug, Koselugo
11:15am, Friday, 21'st Nov 2025
AstraZeneca secures FDA approval to expand Koselugo's use to treat adult NF1 patients with inoperable PN.
AstraZeneca Wins FDA Nod For Koselugo In Adult NF1
01:57pm, Thursday, 20'th Nov 2025
AstraZeneca's (AZN) Alexion unit scored an important milestone on Thursday, saying the FDA has approved Koselugo for adults with neurofibromatosis type 1 who ha
FTSE 100 Live: London and European stocks tumble, bitcoin sell-off deepens
04:16am, Tuesday, 18'th Nov 2025
9.16am: European markets in selling mode After the first hour and a bit of trading, the Footsie is down 0.8%, which is one of the better performances among...
Connor Clark & Lunn Investment Management Ltd. Lowers Holdings in AstraZeneca PLC $AZN
04:36am, Monday, 17'th Nov 2025
Connor Clark and Lunn Investment Management Ltd. lowered its stake in shares of AstraZeneca PLC (NASDAQ: AZN) by 34.1% during the undefined quarter, according to the company in its most recent Form 13
Biopharma companies have confidence in their ability to do deals: BMO's Evan Seigerman
03:19pm, Friday, 14'th Nov 2025
Evan Seigerman, BMO Capital Markets head of health care research, joins 'Power Lunch' to discuss what's behind the recent move in health care stocks, the state of play with GLP-1s and much more.
Health Rounds: Lilly blood thinner tops AstraZeneca's for heart procedure patients with diabetes
07:06am, Friday, 14'th Nov 2025
Blood-thinning drugs that doctors often prescribe interchangeably after procedures to reopen narrowed heart arteries don't work equally well in patients with diabetes, a study from India found.
Allianz SE Purchases 4,315 Shares of AstraZeneca PLC $AZN
04:03am, Friday, 14'th Nov 2025
Allianz SE raised its position in shares of AstraZeneca PLC (NASDAQ: AZN) by 148.6% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The
AstraZeneca leans on its pipeline as $80bn revenue target comes into view
07:49am, Thursday, 13'th Nov 2025
It is not every day that a company makes a habit of turning in positive clinical results at a pace that would make even the most seasoned drug developer blink. Yet AstraZeneca PLC (LSE:AZN, NASDAQ:AZN
Why Astrazeneca (AZN) is a Top Growth Stock for the Long-Term
10:46am, Wednesday, 12'th Nov 2025
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
FTSE 100 hits record high as job market data weakens pound; AstraZeneca shines
07:45am, Tuesday, 11'th Nov 2025
London's export-focused FTSE 100 rose to a new intraday record peak on Tuesday, buoyed by a weakening pound after economic data revealed rising unemployment and slowing wage growth, while drugmaker As
AstraZeneca hits record high, cements lead as UK's biggest stock
03:42am, Tuesday, 11'th Nov 2025
Shares in AstraZeneca rose past their September 2024 peak on Tuesday, hitting a fresh record high and cementing the company's position as the largest UK-listed stock by market value.
Why AstraZeneca Stock Was a Winner Today
05:20pm, Monday, 10'th Nov 2025
The pharmaceutical sector mainstay reported good news about its developmental hypertension drug. It purchased the medicine's maker, CinCor Pharma, in early 2023.
AstraZeneca's Investigational Hypertension Drug Shows Significant Blood Pressure Control In Pivotal Trial
01:39pm, Monday, 10'th Nov 2025
AstraZeneca Plc (NASDAQ:AZN) shared on Monday full data from the Bax24 Phase 3 trial of once-daily 2mg baxdrostat versus placebo, on the reduction of ambulatory systolic blood pressure (SBP), as well
WILMINGTON, Del.--(BUSINESS WIRE)--Positive full results from the Bax24 Phase III trial showed baxdrostat demonstrated a statistically significant and highly clinically meaningful reduction in ambulat
WILMINGTON, Del.--(BUSINESS WIRE)--Positive full results from the NATRON Phase III trial showed AstraZeneca's FASENRA (benralizumab) demonstrated a statistically significant delay in the time to first
